AI-PROGNOSIS - Artificial intelligence-based Parkinson’s disease risk assessment and prognosis
From 01-07-2023 to 30-06-2027
Description
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder1, with a multifactorial aetiology, a heterogeneous manifestation of motor and non-motor symptoms, and no cure, affecting ~10 million people worldwide; a figure expected to nearly double by 20402. PD is often missed or misdiagnosed, as early symptoms are subtle and common with other diseases, allowing for considerable damage to occur before treatment3. Effective, symptomatic treatments, relying mainly on dopaminergic medications, are available, yet selecting the optimal regimen is usually a lengthy, “trial and error” process, leading to critical, costly non-adherence. Overall costs to Europe have been estimated at ~€13.9 billion annually4, with the cost per patient increasing with severity. AI predictive and precision medicine models, and new monitoring technologies, hold the potential to improve PD diagnosis and care5. Personalised risk assessment can lead citizens to suitable healthcare pathways early, enabling timely diagnosis and treatment initiation, while individualised prediction of disease progression and drug response could foster treatment optimization and adherence, improving patients’ quality of life (QoL) and lowering costs associated with advanced disability.
Team
- Christos Chatzichristos, Co-promoter
- Maarten De Vos, Promoter
Financing
Funding: EU Funding - European Funding
Program/Grant Type: HORIZON HLTH - Tools and technologies for a healthy society
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.